Effects of histidine-tag on recombinant human cytochrome P450 3A5 catalytic activity in reconstitution systems

Drug Metabolism Letters

Volumn 3, Issue 4, 2009, Pages 207-211

  Emoto, Chie ^a   Murayama, Norie ^a   Wakiya, Sachiko ^a   Yamazaki, Hiroshi ^a  

^a SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

CYP3A5; E. coli membranes; Histidine; Human; Reconstitution system

Indexed keywords

CYTOCHROME B5; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; HEME; MIDAZOLAM; PHOSPHOLIPID; POLYHISTIDINE TAG; RECOMBINANT ENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE;

ARTICLE; BACTERIAL MEMBRANE; CATALYSIS; DRUG HYDROXYLATION; ENZYME ACTIVITY; ENZYME RECONSTITUTION; ENZYME STRUCTURE; ESCHERICHIA COLI; PLASMID; PRIORITY JOURNAL;

CATALYSIS; CYTOCHROME P-450 CYP3A; CYTOCHROMES B; ESCHERICHIA COLI; HISTIDINE; HUMANS; HYDROXYLATION; MIDAZOLAM; MODELS, MOLECULAR; NADPH-FERRIHEMOPROTEIN REDUCTASE; PHOSPHOLIPIDS; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY;

BACTERIA (MICROORGANISMS);

EID: 74749103579     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231209790218109     Document Type: Article

References (26)

1. Nelson, D. R.; Koymans, L.; Kamataki, T.; Stegeman, J. J.; Feyereisen, R.; Waxman, D. J.; Waterman, M. R.; Gotoh, O.; Coon, M. J.; Estabrook, R. W.; Gunsalus, I. C.; Nebert, D. W. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 1996, 6(1), 1-42.
2. Westlind, A.; Malmebo, S.; Johansson, I.; Otter, C.; Andersson, T. B.; Ingelman-Sundberg, M.; Oscarson, M. Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. Biochem. Biophys. Res. Commun., 2001, 281(5), 1349-1355.
3. Shimada, T.; Yamazaki, H.; Mimura, M.; Inui, Y.; Guengerich, F. P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 1994, 270(1), 414-423.
4. Koch, I.; Weil, R.; Wolbold, R.; Brockmoller, J.; Hustert, E.; Burk, O.; Nuessler, A.; Neuhaus, P.; Eichelbaum, M.; Zanger, U.; Wojnowski, L. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab. Dispos., 2002, 30(10), 1108-1114.
5. Wrighton, S. A.; Brian, W. R.; Sari, M. A.; Iwasaki, M.; Guengerich, F. P.; Raucy, J. L.; Molowa, D. T.; Vandenbranden, M. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol., 1990, 38(2), 207-213.
6. Kuehl, P.; Zhang, J.; Lin, Y.; Lamba, J.; Assem, M.; Schuetz, J.; Watkins, P. B.; Daly, A.; Wrighton, S. A.; Hall, S. D.; Maurel, P.; Relling, M.; Brimer, C.; Yasuda, K.; Venkataramanan, R.; Strom, S.; Thummel, K.; Boguski, M. S.; Schuetz, E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet., 2001, 27(4), 383-391.
7. Niwa, T.; Murayama, N.; Emoto, C.; Yamazaki, H. Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5. Curr. Drug Metab., 2008, 9(1), 20-33.
8. Fukuen, S.; Fukuda, T.; Maune, H.; Ikenaga, Y.; Yamamoto, I.; Inaba, T.; Azuma, J. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics, 2002, 12(4), 331-334.
9. Saeki, M.; Saito, Y.; Nakamura, T.; Murayama, N.; Kim, S. R.; Ozawa, S.; Komamura, K.; Ueno, K.; Kamakura, S.; Nakajima, T.; Saito, H.; Kitamura, Y.; Kamatani, N.; Sawada, J. Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population. Hum. Mutat., 2003, 21(6), 653.
10. Yamaori, S.; Yamazaki, H.; Iwano, S.; Kiyotani, K.; Matsumura, K.; Saito, T.; Parkinson, A.; Nakagawa, K.; Kamataki, T. Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of coregulation of the expression of CYP3A in Japanese livers. Xenobiotica, 2005, 35(1), 69-83.
11. Komori, M.; Nishio, K.; Kitada, M.; Shiramatsu, K.; Muroya, K.; Soma, M.; Nagashima, K.; Kamataki, T. Fetus-specific expression of a form of cytochrome P-450 in human livers. Biochemistry, 1990, 29(18), 4430-4433.
12. Wrighton, S. A.; Stevens, J. C. The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol., 1992, 22(1), 1-21.
13. Emoto, C.; Iwasaki, K. Enzymatic characteristics of CYP3A5 and CYP3A4: a comparison of in vitro kinetic and drug-drug interaction patterns. Xenobiotica, 2006, 36(2-3), 219-233.
14. Okada, Y.; Murayama, N.; Yanagida, C.; Shimizu, M.; Guengerich, F. P.; Yamazaki, H. Drug interactions of thalidomide with midazolam and cyclosporine A: heterotropic cooperativity of human cytochrome P450 3A5. Drug Metab. Dispos., 2009, 37(1), 18-23.
15. Cook, C. S.; Berry, L. M.; Kim, D. H.; Burton, E. G. Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5. Drug Metab. Dispos., 2002, 30(12), 1344-1351.
16. Gibbs, M. A.; Thummel, K. E.; Shen, D. D.; Kunze, K. L. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab. Dispos., 1999, 27(2), 180-187.
17. Patki, K. C.; Von Moltke, L. L.; Greenblatt, D. J. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab. Dispos., 2003, 31(7), 938-944.
18. Yamazaki, H.; Nakamura, M.; Komatsu, T.; Ohyama, K.; Hatanaka, N.; Asahi, S.; Shimada, N.; Guengerich, F. P.; Shimada,T.; Nakajima, M.; Yokoi, T. Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Express. Purif., 2002, 24(3), 329-337.
19. Yamazaki, H.; Gillam, E. M.; Dong, M. S.; Johnson, W. W.; Guengerich, F. P.; Shimada, T. Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: effects of cytochrome P450-P450 and cytochrome P450-b5 interactions. Arch. Biochem. Biophys., 1997, 342(2), 329-337.
20. 5. J. Biol. Chem., 1996, 271(44), 27438-27444.
21. Guengerich, F.P.; Martin, M.V. Purification of cytochromes P450: products of bacterial recombinant expression systems. Methods Mol. Biol., 2006, 320, 31-37.
22. Wray, W.; Boulikas, T.; Wray, V. P.; Hancock, R. Silver staining of proteins in polyacrylamide gels. Anal. Biochem., 1981, 118(1), 197-203.
23. Kronbach, T.; Mathys, D.; Umeno, M.; Gonzalez, F. J.; Meyer, U. A. Oxidation of midazolam and triazolam by human liver cytochrome P450II. Mol. Pharmacol., 1989, 36(1), 89-96.
24. Emoto, C.; Murayama, N.; Yamazaki, H. Effects of enzyme sources on midazolam 1'-hydroxylation activity catalyzed by recombinant cytochrome P450 3A4 in combination with NADPHcytochrome P450 reductase. Drug Metab. Lett., 2008, 2(3), 190-192.
25. Pearson, J. T.; Wahlstrom, J. L.; Dickmann, L. J.; Kumar, S.; Halpert, J. R.; Wienkers, L. C.; Foti, R. S.; Rock, D. A. Differential time-dependent inactivation of P450 3A4 and P450 3A5 by raloxifene: a key role for C239 in quenching reactive intermediates. Chem. Res. Toxicol., 2007, 20(12), 1778-1786.
26. 5 in bacterial membranes. Drug Metab. Dispos., 1999, 27(9), 999-1004.